Literature DB >> 9645639

Immunoapheresis in paraneoplastic pemphigus.

H Schoen1, D Foedinger, K Derfler, G Amann, K Rappersberger, G Stingl, B Volc-Platzer.   

Abstract

BACKGROUND: Paraneoplastic pemphigus was first described in 1990 in 5 patients with extensive mucocutaneous erosions, a distinct set of autoantibodies, and underlying neoplasia. Since then, patients described have been middle-aged, have suffered from prognostically unfavorable malignant neoplasms, and have responded poorly to immunosuppressive agents. OBSERVATION: A 16-year-old boy was examined with extensive oral erosions, halitosis that interfered with his quality of life, and rapid weight loss. The suspected clinical diagnosis of paraneoplastic pemphigus was confirmed by histopathological, immunofluorescence, and biochemical (eg, immunoblotting and immunoprecipitation) findings as well as by the demonstration of an inflammatory myofibroblastic tumor of the left retroclavicular region. Despite administration of corticosteroids, followed by excision of the neoplasm, clinical symptoms improved only slightly, and autoantibody titers decreased only marginally. We therefore initiated an immunoapheresis regimen with the use of sheep anti-human-IgG bead-formed agarose gel (Sepharose; Pharmacia Biotech Comp, Vienna, Austria), which led to the disappearance of circulating autoantibodies and the patient's recovery.
CONCLUSION: Immunoapheresis may represent a novel therapeutic option for patients with paraneoplastic pemphigus who show little improvement after curative treatment of their neoplasms.

Entities:  

Mesh:

Year:  1998        PMID: 9645639     DOI: 10.1001/archderm.134.6.706

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  4 in total

Review 1.  [Immunoadsorption in dermatology].

Authors:  Franziska Hübner; Michael Kasperkiewicz; Detlef Zillikens; Enno Schmidt
Journal:  Hautarzt       Date:  2019-01       Impact factor: 0.751

Review 2.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

3.  A middle-aged man presenting with unexplained mucosal erosions and progressive dyspnoea.

Authors:  W J Healy; S Peters; S P Nana-Sinkam
Journal:  BMJ Case Rep       Date:  2015-05-07

4.  Therapy of autoimmune bullous diseases.

Authors:  Diya F Mutasim
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.